7.3
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples…
Nondepolarizing neuromuscular blockers bind to the nAChR on the motor end plate to prevent membrane depolarization and muscular contractions.
Most nondepolarizing blockers resemble the endogenous ligand ACh, and so they competitively bind to the nAChR. However, unlike ACh, their bulky structure prevents the conformational changes necessary for receptor activation.
As a result, ion channels remain closed, preventing muscle end plate depolarization. This leads to neuromuscular transmission blockade and muscle relaxation.
The induced effect can be reversed by administering AChE enzyme inhibitors. They block AChE, and inhibit degradation of ACh elevating its concentration.
However, when the nondepolarizing blockers are administered in large doses, they block the sodium channel pore as well. This results in an intense neuromuscular blockade, which is difficult to reverse using AChE inhibitors.
View the full transcript and gain access to JoVE Core videos
Q1: How do nondepolarizing neuromuscular blockers prevent muscle contraction?
Nondepolarizing blockers bind competitively to nicotinic acetylcholine receptors at the motor end plate, mimicking acetylcholine's structure. However, their bulky molecular form prevents the conformational changes needed for receptor activation. This keeps ion channels closed, blocking membrane depolarization and preventing muscle contraction through neuromuscular transmission blockade.
Q2: Why can't nondepolarizing blockers activate the acetylcholine receptor like acetylcholine does?
Although nondepolarizing blockers structurally resemble acetylcholine, their bulky structure prevents the conformational changes necessary for receptor activation. Without these structural changes, ion channels remain closed and the receptor cannot be activated, resulting in competitive antagonism at the neuromuscular junction.
Q3: How do acetylcholinesterase inhibitors reverse nondepolarizing neuromuscular blockade?
Acetylcholinesterase inhibitors block the enzyme that degrades acetylcholine, elevating its concentration at the neuromuscular junction. Increased acetylcholine competes with the blocker for receptor binding sites, displacing it and restoring neuromuscular transmission. This reversal works effectively at normal blocker doses.
Q4: What happens when nondepolarizing blockers are administered at high doses?
At high doses, nondepolarizing blockers directly block sodium channel pores in addition to competitive receptor antagonism. This results in intense neuromuscular blockade that is difficult or impossible to reverse using acetylcholinesterase inhibitors, since the blockade is no longer purely competitive.
Q5: What are common examples of nondepolarizing neuromuscular blockers?
Common nondepolarizing blockers include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, poorly absorbed orally, and primarily excreted via the kidneys, making them suitable for clinical use during anesthesia.
Q6: Why is competitive antagonism important for reversing nondepolarizing blockade?
Competitive antagonism means the blocker and acetylcholine compete for the same receptor binding site. This allows acetylcholinesterase inhibitors to increase acetylcholine concentration, which can outcompete and displace the blocker, restoring neuromuscular transmission and muscle function.
Q7: How do nondepolarizing blockers differ from depolarizing blockers in their mechanism?
Nondepolarizing blockers competitively block receptors without activating them, preventing depolarization. In contrast, depolarizing blockers activate the receptor and cause sustained depolarization. This fundamental difference means nondepolarizing blockade can be reversed with acetylcholinesterase inhibitors, while depolarizing blockade cannot.